Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA, ARIEL3 investigators

Open source

DOI: 10.1016/s0140-6736(17)32440-6
Published: 2017 Oct 28
Container: Lancet (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-17-32440-6,
  title = {Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.},
  author = {Coleman RL and Oza AM and Lorusso D and Aghajanian C and Oaknin A and Dean A and Colombo N and Weberpals JI and Clamp A and Scambia G and Leary A and Holloway RW and Gancedo MA and Fong PC and Goh JC and O'Malley DM and Armstrong DK and Garcia-Donas J and Swisher EM and Floquet A and Konecny GE and McNeish IA and Scott CL and Cameron T and Maloney L and Isaacson J and Goble S and Grace C and Harding TC and Raponi M and Sun J and Lin KK and Giordano H and Ledermann JA and ARIEL3 investigators},
  year = {2017},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(17)32440-6},
  url = {https://doi.org/10.1016/s0140-6736(17)32440-6}
}

RIS

TY  - JOUR
TI  - Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
AU  - Coleman RL
AU  - Oza AM
AU  - Lorusso D
AU  - Aghajanian C
AU  - Oaknin A
AU  - Dean A
AU  - Colombo N
AU  - Weberpals JI
AU  - Clamp A
AU  - Scambia G
AU  - Leary A
AU  - Holloway RW
AU  - Gancedo MA
AU  - Fong PC
AU  - Goh JC
AU  - O'Malley DM
AU  - Armstrong DK
AU  - Garcia-Donas J
AU  - Swisher EM
AU  - Floquet A
AU  - Konecny GE
AU  - McNeish IA
AU  - Scott CL
AU  - Cameron T
AU  - Maloney L
AU  - Isaacson J
AU  - Goble S
AU  - Grace C
AU  - Harding TC
AU  - Raponi M
AU  - Sun J
AU  - Lin KK
AU  - Giordano H
AU  - Ledermann JA
AU  - ARIEL3 investigators
PY  - 2017
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(17)32440-6
UR  - https://doi.org/10.1016/s0140-6736(17)32440-6
ER  -

APA

RL, C., AM, O., D, L., C, A., A, O., A, D., N, C., JI, W., A, C., G, S., A, L., RW, H., MA, G., PC, F., JC, G., DM, O., DK, A., J, G., EM, S., A, F., GE, K., IA, M., CL, S., T, C., L, M., J, I., S, G., C, G., TC, H., M, R., J, S., KK, L., H, G., JA, L., & investigators, A. (2017). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(17)32440-6

Source records

pubmed · retrieved 2026-09-27T09:56:50.734Z